ShiraTronics Secures $66M to Advance Novel Therapy for Migraine nextdigitalhealth.com

MedTech startup ShiraTronics has secured $66 million in Series B funding round to advance implantable neuromodulation device for treatment-resistant migraine to FDA-approved pivotal clinical trials, the company announced last Wednesday.

Co-founded in 2018 by Mudit Jain, Ph. D., CEO and partner at Treo Ventures and Lynn Elliott, ShiraTronics leverages advanced technologies to develop an effective therapy for chronic migraines.